View Future GrowthPrim 過去の業績過去 基準チェック /56Primは、平均年間3.7%の収益成長を遂げていますが、 Medical Equipment業界の収益は、年間 成長しています。収益は、平均年間6.7% 10.2%収益成長率で 成長しています。 Primの自己資本利益率は12.1%であり、純利益率は6.6%です。主要情報3.72%収益成長率3.99%EPS成長率Medical Equipment 業界の成長12.30%収益成長率10.23%株主資本利益率12.12%ネット・マージン6.62%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Mar 30Full year 2025 earnings released: EPS: €0.98 (vs €0.64 in FY 2024)Full year 2025 results: EPS: €0.98 (up from €0.64 in FY 2024). Revenue: €253.6m (up 8.7% from FY 2024). Net income: €16.7m (up 53% from FY 2024). Profit margin: 6.6% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 17Prim's (BME:PRM) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for Prim, S.A.'s ( BME:PRM ) stock hasn't moved much. Our analysis...Reported Earnings • Apr 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €235.0m (up 8.5% from FY 2023). Net income: €10.9m (down 14% from FY 2023). Profit margin: 4.6% (down from 5.9% in FY 2023). The decrease in margin was driven by higher expenses.Reported Earnings • Sep 30First half 2024 earnings released: EPS: €0.40 (vs €0.47 in 1H 2023)First half 2024 results: EPS: €0.40 (down from €0.47 in 1H 2023). Revenue: €119.7m (up 10% from 1H 2023). Net income: €6.77m (down 16% from 1H 2023). Profit margin: 5.7% (down from 7.4% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year.分析記事 • Apr 16Investors Shouldn't Be Too Comfortable With Prim's (BME:PRM) EarningsPrim, S.A.'s ( BME:PRM ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.50 (vs €1.01 in FY 2021)Full year 2022 results: EPS: €0.50 (down from €1.01 in FY 2021). Revenue: €197.2m (up 17% from FY 2021). Net income: €8.45m (down 52% from FY 2021). Profit margin: 4.3% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • May 25Prim, S.A., Annual General Meeting, Jun 25, 2026Prim, S.A., Annual General Meeting, Jun 25, 2026. Location: avenida del llano castellano 43, planta 3, fuencarral, madrid., SpainReported Earnings • Mar 30Full year 2025 earnings released: EPS: €0.98 (vs €0.64 in FY 2024)Full year 2025 results: EPS: €0.98 (up from €0.64 in FY 2024). Revenue: €253.6m (up 8.7% from FY 2024). Net income: €16.7m (up 53% from FY 2024). Profit margin: 6.6% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Declared Dividend • Feb 26Dividend of €0.11 announcedShareholders will receive a dividend of €0.11. Ex-date: 10th March 2026 Payment date: 12th March 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Board Change • Jan 30Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director María Rodríguez was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Dec 19Prim (BME:PRM) Has Announced A Dividend Of €0.1053The board of Prim, S.A. ( BME:PRM ) has announced that it will pay a dividend on the 23rd of December, with investors...Declared Dividend • Dec 18Dividend of €0.11 announcedShareholders will receive a dividend of €0.11. Ex-date: 19th December 2025 Payment date: 23rd December 2025 Dividend yield will be 2.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.分析記事 • Sep 17Prim's (BME:PRM) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for Prim, S.A.'s ( BME:PRM ) stock hasn't moved much. Our analysis...分析記事 • Jul 07Prim's (BME:PRM) Dividend Will Be Increased To €0.1855Prim, S.A. ( BME:PRM ) has announced that it will be increasing its dividend from last year's comparable payment on the...Declared Dividend • Jul 07Dividend of €0.19 announcedShareholders will receive a dividend of €0.19. Ex-date: 16th July 2025 Payment date: 18th July 2025 Dividend yield will be 3.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (42% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • May 28Prim, S.A., Annual General Meeting, Jun 29, 2025Prim, S.A., Annual General Meeting, Jun 29, 2025. Location: avenida del llano castellano 43, planta 3, fuencarral., madrid SpainNew Risk • Apr 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Paying a dividend despite having no free cash flows.Reported Earnings • Apr 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €235.0m (up 8.5% from FY 2023). Net income: €10.9m (down 14% from FY 2023). Profit margin: 4.6% (down from 5.9% in FY 2023). The decrease in margin was driven by higher expenses.Declared Dividend • Mar 03Dividend of €0.089 announcedShareholders will receive a dividend of €0.089. Ex-date: 11th March 2025 Payment date: 13th March 2025 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (67% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 26% to shift the payout ratio to a potentially unsustainable range, which is more than the 1.5% EPS decline seen over the last 5 years.Reported Earnings • Sep 30First half 2024 earnings released: EPS: €0.40 (vs €0.47 in 1H 2023)First half 2024 results: EPS: €0.40 (down from €0.47 in 1H 2023). Revenue: €119.7m (up 10% from 1H 2023). Net income: €6.77m (down 16% from 1H 2023). Profit margin: 5.7% (down from 7.4% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year.分析記事 • Jul 11Prim (BME:PRM) Is Increasing Its Dividend To €0.1838Prim, S.A. ( BME:PRM ) will increase its dividend from last year's comparable payment on the 19th of July to €0.1838...Declared Dividend • Jul 08Dividend of €0.18 announcedShareholders will receive a dividend of €0.18. Ex-date: 17th July 2024 Payment date: 19th July 2024 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (36% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.7% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to remain steady over the next year, which should provide adequate earnings cover for the dividend.Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 6.5% to €10.50. The fair value is estimated to be €8.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat.Buy Or Sell Opportunity • Jun 04Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 2.0% to €10.35. The fair value is estimated to be €8.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat.分析記事 • Apr 16Investors Shouldn't Be Too Comfortable With Prim's (BME:PRM) EarningsPrim, S.A.'s ( BME:PRM ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...Declared Dividend • Mar 08Dividend of €0.089 announcedShareholders will receive a dividend of €0.089. Ex-date: 13th March 2024 Payment date: 15th March 2024 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (64% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 44% over the next year, which should provide support to the dividend and adequate earnings cover.New Risk • Feb 11New major risk - Revenue and earnings growthEarnings have declined by 4.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin).New Risk • Oct 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (98% cash payout ratio). Share price has been volatile over the past 3 months (4.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin).New Risk • Jun 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.3% net profit margin).Upcoming Dividend • Mar 06Upcoming dividend of €0.089 per share at 4.6% yieldEligible shareholders must have bought the stock before 13 March 2023. Payment date: 16 March 2023. Payout ratio is a comfortable 47% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.8%).Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.50 (vs €1.01 in FY 2021)Full year 2022 results: EPS: €0.50 (down from €1.01 in FY 2021). Revenue: €197.2m (up 17% from FY 2021). Net income: €8.45m (down 52% from FY 2021). Profit margin: 4.3% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • Dec 20Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 27 December 2022. Payment date: 29 December 2022. Payout ratio is a comfortable 50% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.7%).Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Independent Director Maria Belen Amatriain Corbi is the most experienced director on the board, commencing their role in 2015. Independent Director Mar Mateo was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Maria Belen Amatriain Corbi was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.分析記事 • Apr 02Here's What To Make Of Prim's (BME:PRM) Decelerating Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Upcoming Dividend • Mar 02Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 09 March 2022. Payment date: 11 March 2022. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.6%). Higher than average of industry peers (1.2%).Reported Earnings • Feb 27Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.01 (up from €0.40 in FY 2020). Revenue: €168.5m (up 14% from FY 2020). Net income: €17.4m (up 152% from FY 2020). Profit margin: 10% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year.Upcoming Dividend • Dec 08Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 14 December 2021. Payment date: 16 December 2021. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.4%). Higher than average of industry peers (1.0%).Reported Earnings • Aug 04Second quarter 2021 earnings released: EPS €0.27 (vs €0.059 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €44.5m (up 51% from 2Q 2020). Net income: €4.54m (up 338% from 2Q 2020). Profit margin: 10% (up from 3.5% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.分析記事 • May 25Does Prim (BME:PRM) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • May 07Returns On Capital At Prim (BME:PRM) Have StalledIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Reported Earnings • Apr 28Full year 2020 earnings released: EPS €0.40 (vs €0.65 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.分析記事 • Mar 06Did You Participate In Any Of Prim's (BME:PRM) Respectable 40% Return?Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 25New 90-day high: €10.60The company is up 15% from its price of €9.20 on 27 November 2020. The Spanish market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.分析記事 • Feb 19Is Prim (BME:PRM) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is New 90 Day High Low • Feb 06New 90-day high: €9.94The company is up 10.0% from its price of €9.04 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period.分析記事 • Feb 01Should You Buy Prim, S.A. (BME:PRM) For Its Dividend?Is Prim, S.A. ( BME:PRM ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can...分析記事 • Jan 16What Do The Returns On Capital At Prim (BME:PRM) Tell Us?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...分析記事 • Jan 01Is Prim, S.A.'s (BME:PRM) Recent Stock Performance Influenced By Its Financials In Any Way?Most readers would already know that Prim's (BME:PRM) stock increased by 6.6% over the past three months. Given that...Is New 90 Day High Low • Dec 31New 90-day high: €9.70The company is up 7.0% from its price of €9.10 on 02 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 7.0% over the same period.分析記事 • Dec 16What Percentage Of Prim, S.A. (BME:PRM) Shares Do Insiders Own?A look at the shareholders of Prim, S.A. ( BME:PRM ) can tell us which group is most powerful. Institutions will often...分析記事 • Nov 25Prim's(BME:PRM) Share Price Is Down 19% Over The Past Year.Investors can approximate the average market return by buying an index fund. While individual stocks can be big...Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS €0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €37.0m (up 11% from 3Q 2019). Net income: €2.58m (up 87% from 3Q 2019). Profit margin: 7.0% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Nov 12New 90-day high: €9.68The company is up 5.0% from its price of €9.18 on 14 August 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 2.0% over the same period.Is New 90 Day High Low • Oct 19New 90-day low: €8.86The company is down 11% from its price of €9.90 on 21 July 2020. The Spanish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period.分析記事 • Jun 17Prim, S.A.'s (BME:PRM) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Prim (BME:PRM) has had a great run on the share market with its stock up by a significant 11% over the last three...収支内訳Prim の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史BME:PRM 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 252521792030 Sep 252461690030 Jun 252411588031 Mar 252371387031 Dec 242331186030 Sep 242301185030 Jun 242281184031 Mar 242221282031 Dec 232171380030 Sep 232121180030 Jun 232071079031 Mar 23202977031 Dec 22197874030 Sep 221921175030 Jun 221861475031 Mar 221811567031 Dec 211691758030 Sep 211681565030 Jun 211611454031 Mar 211461036031 Dec 20147754030 Sep 201471157030 Jun 20143957031 Mar 201541136031 Dec 191511157030 Sep 191461255030 Jun 191421354031 Mar 191371453031 Dec 181341452030 Sep 181321449030 Jun 181281448031 Mar 181241548031 Dec 171211447030 Sep 171171447030 Jun 171161446031 Mar 171141345031 Dec 161101344030 Sep 161071141030 Jun 161061141031 Mar 161021140031 Dec 15991140030 Sep 15991139030 Jun 159711390質の高い収益: PRMは 高品質の収益 を持っています。利益率の向上: PRMの現在の純利益率 (6.6%)は、昨年(4.7%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PRMの収益は過去 5 年間で年間3.7%増加しました。成長の加速: PRMの過去 1 年間の収益成長率 ( 52.8% ) は、5 年間の平均 ( 年間3.7%を上回っています。収益対業界: PRMの過去 1 年間の収益成長率 ( 52.8% ) はMedical Equipment業界-0.8%を上回りました。株主資本利益率高いROE: PRMの 自己資本利益率 ( 12.1% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 09:25終値2026/06/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Prim, S.A. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Marisa Luisa Mazo FajardoGVC Gaesco Valores
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: €0.98 (vs €0.64 in FY 2024)Full year 2025 results: EPS: €0.98 (up from €0.64 in FY 2024). Revenue: €253.6m (up 8.7% from FY 2024). Net income: €16.7m (up 53% from FY 2024). Profit margin: 6.6% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 17Prim's (BME:PRM) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for Prim, S.A.'s ( BME:PRM ) stock hasn't moved much. Our analysis...
Reported Earnings • Apr 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €235.0m (up 8.5% from FY 2023). Net income: €10.9m (down 14% from FY 2023). Profit margin: 4.6% (down from 5.9% in FY 2023). The decrease in margin was driven by higher expenses.
Reported Earnings • Sep 30First half 2024 earnings released: EPS: €0.40 (vs €0.47 in 1H 2023)First half 2024 results: EPS: €0.40 (down from €0.47 in 1H 2023). Revenue: €119.7m (up 10% from 1H 2023). Net income: €6.77m (down 16% from 1H 2023). Profit margin: 5.7% (down from 7.4% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year.
分析記事 • Apr 16Investors Shouldn't Be Too Comfortable With Prim's (BME:PRM) EarningsPrim, S.A.'s ( BME:PRM ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.50 (vs €1.01 in FY 2021)Full year 2022 results: EPS: €0.50 (down from €1.01 in FY 2021). Revenue: €197.2m (up 17% from FY 2021). Net income: €8.45m (down 52% from FY 2021). Profit margin: 4.3% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • May 25Prim, S.A., Annual General Meeting, Jun 25, 2026Prim, S.A., Annual General Meeting, Jun 25, 2026. Location: avenida del llano castellano 43, planta 3, fuencarral, madrid., Spain
Reported Earnings • Mar 30Full year 2025 earnings released: EPS: €0.98 (vs €0.64 in FY 2024)Full year 2025 results: EPS: €0.98 (up from €0.64 in FY 2024). Revenue: €253.6m (up 8.7% from FY 2024). Net income: €16.7m (up 53% from FY 2024). Profit margin: 6.6% (up from 4.7% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Declared Dividend • Feb 26Dividend of €0.11 announcedShareholders will receive a dividend of €0.11. Ex-date: 10th March 2026 Payment date: 12th March 2026 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (32% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Board Change • Jan 30Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director María Rodríguez was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Dec 19Prim (BME:PRM) Has Announced A Dividend Of €0.1053The board of Prim, S.A. ( BME:PRM ) has announced that it will pay a dividend on the 23rd of December, with investors...
Declared Dividend • Dec 18Dividend of €0.11 announcedShareholders will receive a dividend of €0.11. Ex-date: 19th December 2025 Payment date: 23rd December 2025 Dividend yield will be 2.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (40% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 44% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
分析記事 • Sep 17Prim's (BME:PRM) Solid Profits Have Weak FundamentalsDespite posting some strong earnings, the market for Prim, S.A.'s ( BME:PRM ) stock hasn't moved much. Our analysis...
分析記事 • Jul 07Prim's (BME:PRM) Dividend Will Be Increased To €0.1855Prim, S.A. ( BME:PRM ) has announced that it will be increasing its dividend from last year's comparable payment on the...
Declared Dividend • Jul 07Dividend of €0.19 announcedShareholders will receive a dividend of €0.19. Ex-date: 16th July 2025 Payment date: 18th July 2025 Dividend yield will be 3.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (42% earnings payout ratio) and cash flows (71% cash payout ratio). The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 56% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • May 28Prim, S.A., Annual General Meeting, Jun 29, 2025Prim, S.A., Annual General Meeting, Jun 29, 2025. Location: avenida del llano castellano 43, planta 3, fuencarral., madrid Spain
New Risk • Apr 13New major risk - Revenue sizeThe company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risk Paying a dividend despite having no free cash flows.
Reported Earnings • Apr 04Full year 2024 earnings releasedFull year 2024 results: Revenue: €235.0m (up 8.5% from FY 2023). Net income: €10.9m (down 14% from FY 2023). Profit margin: 4.6% (down from 5.9% in FY 2023). The decrease in margin was driven by higher expenses.
Declared Dividend • Mar 03Dividend of €0.089 announcedShareholders will receive a dividend of €0.089. Ex-date: 11th March 2025 Payment date: 13th March 2025 Dividend yield will be 3.5%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (67% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.3% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 26% to shift the payout ratio to a potentially unsustainable range, which is more than the 1.5% EPS decline seen over the last 5 years.
Reported Earnings • Sep 30First half 2024 earnings released: EPS: €0.40 (vs €0.47 in 1H 2023)First half 2024 results: EPS: €0.40 (down from €0.47 in 1H 2023). Revenue: €119.7m (up 10% from 1H 2023). Net income: €6.77m (down 16% from 1H 2023). Profit margin: 5.7% (down from 7.4% in 1H 2023). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 10% per year.
分析記事 • Jul 11Prim (BME:PRM) Is Increasing Its Dividend To €0.1838Prim, S.A. ( BME:PRM ) will increase its dividend from last year's comparable payment on the 19th of July to €0.1838...
Declared Dividend • Jul 08Dividend of €0.18 announcedShareholders will receive a dividend of €0.18. Ex-date: 17th July 2024 Payment date: 19th July 2024 Dividend yield will be 3.4%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (36% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.7% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to remain steady over the next year, which should provide adequate earnings cover for the dividend.
Buy Or Sell Opportunity • Jul 08Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 6.5% to €10.50. The fair value is estimated to be €8.57, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat.
Buy Or Sell Opportunity • Jun 04Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 2.0% to €10.35. The fair value is estimated to be €8.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years, while earnings per share has been flat.
分析記事 • Apr 16Investors Shouldn't Be Too Comfortable With Prim's (BME:PRM) EarningsPrim, S.A.'s ( BME:PRM ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...
Declared Dividend • Mar 08Dividend of €0.089 announcedShareholders will receive a dividend of €0.089. Ex-date: 13th March 2024 Payment date: 15th March 2024 Dividend yield will be 2.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (64% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 2.9% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 44% over the next year, which should provide support to the dividend and adequate earnings cover.
New Risk • Feb 11New major risk - Revenue and earnings growthEarnings have declined by 4.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin).
New Risk • Oct 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.0% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (98% cash payout ratio). Share price has been volatile over the past 3 months (4.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.7% net profit margin).
New Risk • Jun 30New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 29% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.0% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (4.3% net profit margin).
Upcoming Dividend • Mar 06Upcoming dividend of €0.089 per share at 4.6% yieldEligible shareholders must have bought the stock before 13 March 2023. Payment date: 16 March 2023. Payout ratio is a comfortable 47% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.8%).
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.50 (vs €1.01 in FY 2021)Full year 2022 results: EPS: €0.50 (down from €1.01 in FY 2021). Revenue: €197.2m (up 17% from FY 2021). Net income: €8.45m (down 52% from FY 2021). Profit margin: 4.3% (down from 10% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Europe. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • Dec 20Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 27 December 2022. Payment date: 29 December 2022. Payout ratio is a comfortable 50% but the company is not cash flow positive. Trailing yield: 4.6%. Lower than top quartile of Spanish dividend payers (6.1%). Higher than average of industry peers (1.7%).
Board Change • Nov 16Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. 4 independent directors (6 non-independent directors). Independent Director Maria Belen Amatriain Corbi is the most experienced director on the board, commencing their role in 2015. Independent Director Mar Mateo was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Maria Belen Amatriain Corbi was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
分析記事 • Apr 02Here's What To Make Of Prim's (BME:PRM) Decelerating Rates Of ReturnIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Upcoming Dividend • Mar 02Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 09 March 2022. Payment date: 11 March 2022. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.6%). Higher than average of industry peers (1.2%).
Reported Earnings • Feb 27Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: EPS: €1.01 (up from €0.40 in FY 2020). Revenue: €168.5m (up 14% from FY 2020). Net income: €17.4m (up 152% from FY 2020). Profit margin: 10% (up from 4.7% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 15%, compared to a 17% growth forecast for the industry in Spain. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has increased by 8% per year.
Upcoming Dividend • Dec 08Upcoming dividend of €0.089 per shareEligible shareholders must have bought the stock before 14 December 2021. Payment date: 16 December 2021. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Spanish dividend payers (5.4%). Higher than average of industry peers (1.0%).
Reported Earnings • Aug 04Second quarter 2021 earnings released: EPS €0.27 (vs €0.059 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €44.5m (up 51% from 2Q 2020). Net income: €4.54m (up 338% from 2Q 2020). Profit margin: 10% (up from 3.5% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
分析記事 • May 25Does Prim (BME:PRM) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • May 07Returns On Capital At Prim (BME:PRM) Have StalledIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Reported Earnings • Apr 28Full year 2020 earnings released: EPS €0.40 (vs €0.65 in FY 2019)The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 06Did You Participate In Any Of Prim's (BME:PRM) Respectable 40% Return?Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: €147.3m (down 2.4% from FY 2019). Net income: €6.92m (down 38% from FY 2019). Profit margin: 4.7% (down from 7.4% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 25New 90-day high: €10.60The company is up 15% from its price of €9.20 on 27 November 2020. The Spanish market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 11% over the same period.
分析記事 • Feb 19Is Prim (BME:PRM) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Is New 90 Day High Low • Feb 06New 90-day high: €9.94The company is up 10.0% from its price of €9.04 on 06 November 2020. The Spanish market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period.
分析記事 • Feb 01Should You Buy Prim, S.A. (BME:PRM) For Its Dividend?Is Prim, S.A. ( BME:PRM ) a good dividend stock? How can we tell? Dividend paying companies with growing earnings can...
分析記事 • Jan 16What Do The Returns On Capital At Prim (BME:PRM) Tell Us?If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...
分析記事 • Jan 01Is Prim, S.A.'s (BME:PRM) Recent Stock Performance Influenced By Its Financials In Any Way?Most readers would already know that Prim's (BME:PRM) stock increased by 6.6% over the past three months. Given that...
Is New 90 Day High Low • Dec 31New 90-day high: €9.70The company is up 7.0% from its price of €9.10 on 02 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Medical Equipment industry, which is also up 7.0% over the same period.
分析記事 • Dec 16What Percentage Of Prim, S.A. (BME:PRM) Shares Do Insiders Own?A look at the shareholders of Prim, S.A. ( BME:PRM ) can tell us which group is most powerful. Institutions will often...
分析記事 • Nov 25Prim's(BME:PRM) Share Price Is Down 19% Over The Past Year.Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
Reported Earnings • Nov 16Third quarter 2020 earnings released: EPS €0.15The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €37.0m (up 11% from 3Q 2019). Net income: €2.58m (up 87% from 3Q 2019). Profit margin: 7.0% (up from 4.1% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Nov 12New 90-day high: €9.68The company is up 5.0% from its price of €9.18 on 14 August 2020. The Spanish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Medical Equipment industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Oct 19New 90-day low: €8.86The company is down 11% from its price of €9.90 on 21 July 2020. The Spanish market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is flat over the same period.
分析記事 • Jun 17Prim, S.A.'s (BME:PRM) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Prim (BME:PRM) has had a great run on the share market with its stock up by a significant 11% over the last three...